Angeles Wealth Management LLC Takes Position in Kenvue Inc. (NYSE:KVUE)

Angeles Wealth Management LLC bought a new stake in shares of Kenvue Inc. (NYSE:KVUE) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 10,118 shares of the company’s stock, valued at approximately $216,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of KVUE. AMF Tjanstepension AB boosted its position in shares of Kenvue by 187.3% during the 3rd quarter. AMF Tjanstepension AB now owns 120,477 shares of the company’s stock valued at $2,787,000 after acquiring an additional 78,540 shares during the last quarter. Atomi Financial Group Inc. bought a new position in shares of Kenvue during the 3rd quarter valued at approximately $212,000. Livforsakringsbolaget Skandia Omsesidigt boosted its position in shares of Kenvue by 291.9% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 16,624 shares of the company’s stock valued at $385,000 after acquiring an additional 12,382 shares during the last quarter. Exchange Traded Concepts LLC lifted its position in Kenvue by 371.7% in the third quarter. Exchange Traded Concepts LLC now owns 29,887 shares of the company’s stock worth $691,000 after buying an additional 23,551 shares during the last quarter. Finally, Willis Investment Counsel lifted its position in Kenvue by 19.8% in the third quarter. Willis Investment Counsel now owns 883,752 shares of the company’s stock worth $20,441,000 after buying an additional 146,075 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Performance

Shares of Kenvue stock opened at $20.60 on Tuesday. The firm has a market cap of $39.49 billion, a P/E ratio of 38.86, a P/E/G ratio of 2.16 and a beta of 1.45. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The stock’s fifty day moving average price is $21.54 and its 200-day moving average price is $22.00.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, equities research analysts expect that Kenvue Inc. will post 1.05 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be paid a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.98%. Kenvue’s dividend payout ratio (DPR) is presently 154.72%.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Canaccord Genuity Group lowered their price target on Kenvue from $27.00 to $24.00 and set a “buy” rating for the company in a research report on Friday. Bank of America raised their price target on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. Barclays lowered their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research report on Friday, January 17th. Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $21.00 to $26.00 in a research report on Monday, January 6th. Finally, Deutsche Bank Aktiengesellschaft downgraded Kenvue from a “buy” rating to a “hold” rating and lowered their price target for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $23.00.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.